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ABSTRACT
Enterococci are leading causes of hospital-acquired infections that are often difﬁcult to treat because of
high-level aminoglycoside and glycopeptide resistance. Vancomycin-resistant enterococci are a global
problem, and have been isolated with increasing frequency in hospitals in Brazil. The objective of this
study was to determine the genetic relatedness of vancomycin-resistant Enterococcus faecium (VREFM)
and vancomycin-sensitive E. faecium (VSEFM) isolated from human infections and faecal sources in
Brazil, and to compare these isolates with those from domesticated animals. Isolates (n = 56) were
classiﬁed by multilocus sequence typing (MLST) and assessed for putative virulence traits. The acm gene
was detected in 98% of all isolates. The 56 isolates studied comprised 26 different MLST types. VSEFM
isolates from the faeces of pigs were found to be distinct from all human isolates characterised
previously by MLST, and were assigned new sequence type (ST) numbers. VREFM isolates were
represented by four different STs (ST-114, ST-17, ST-281, ST-50). Among the 26 STs identiﬁed in this
study, eBURST detected three groups of STs with related allelic proﬁles, and 19 unrelated STs. Among
E. faecium isolates from Brazil, the esp gene was restricted to vancomycin-resistant isolates. Furthermore,
isolates classiﬁed as ST-17 by MLST, an epidemic strain type isolated internationally with the purK-1
gene, were found among VREFM isolates from Brazil that also harboured the esp and hyl genes.
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INTRODUCTION
Enterococcus faecium causes a large proportion of
human enterococcal infections, which can be
extremely difﬁcult to treat because of resistance
to glycopeptides and ampicillin, and high-level
resistance to aminoglycosides [1]. Six different
phenotypes for vancomycin-resistant enterococci
(VRE) have been described: VanA, VanB, VanC,
VanD, VanE and VanG [2–4]. In Brazil, VRE have
recently become endemic in hospitals. The ﬁrst
vancomycin-resistant enterococcal strain identi-
ﬁed was a divergent VanD strain of E. faecium
isolated in 1996 from a patient with aplastic
anaemia [3,5]. The ﬁrst documented case of VanA
E. faecium infection occurred in Brazil during
1997. The strain was isolated from a case of
meningitis in Sa˜o Paulo [6]. One year later, several
vancomycin-resistant E. faecium and Enterococcus
faecalis strains were isolated from the same hos-
pital in Sa˜o Paulo, providing evidence of an
outbreak caused by VanA enterococci [7]. A study
of these isolates identiﬁed several different clones
of E. faecium. VRE have also been isolated from
different hospitals in Sa˜o Paulo, indicating inter-
hospital dissemination [8–10].
In addition to antibiotic resistance, putative
virulence factors described in vancomycin-resist-
ant E. faecium (VREFM) include a collagen-bind-
ing adhesin (acm) and hyaluronidase (hyl) [11,12].
Rice et al. [12] described an open reading frame,
designated hylEfm, which had a deduced amino-
acid sequence with signiﬁcant identity to known
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hyaluronidase genes. hylEfm has been detected
mostly in multiresistant E. faecium isolates from
non-stool cultures from patients in hospitals in
the USA [12], but has also been found in an
endemic VREFM strain in a survey in Taiwan
[13]. A collagen-binding adhesin of E. faecium
(Acm), expressed on the surface of the bacterium,
was characterised as a new member of the
MSCRAMMs (Microbial Surface Components
Recognising Adhesin Matrix Molecules) family.
Despite the detection of the acm gene in all 32
isolates studied, the Acm phenotype is identiﬁ-
able only in certain clinical isolates [11]. The
attachment of Acm-positive E. faecium to collagen
type I has been studied, but a role for Acm in
E. faecium pathogenesis has not yet been demon-
strated [11].
Gelatinase, aggregation substance and cytoly-
sin are virulence factors found in E. faecalis,
although they have also been sought among E.
faecium isolates [14–16]. Gelatinase (GelE) is an
extra-cellular zinc metallo-endopeptidase that
hydrolyses collagen, gelatin and small peptides
[17] and plays a role in bioﬁlm development [18–
20]. Aggregation substance, encoded by asc10,
asa1 and other related genes, represents a family
of pheromone-inducible surface proteins that
promote aggregation during bacterial conjugation
[21]. Cytolysin has bacteriocin activity and is also
a haemolytic toxin for human, horse and rabbit
erythrocytes [22]. Cytolysin and aggregation sub-
stance appears to act synergically to enhance the
severity of endocarditis [23].
A virulence factor found in both E. faecalis and
E. faecium is enterococcal surface protein (Esp),
encoded by the esp gene [15,24,25]. Esp is a
surface protein that enhances bioﬁlm formation
by E. faecalis in the presence of glucose [26], and is
one of the virulence factors encoded by the
pathogenicity island that is present in both E. fae-
calis [27] and E. faecium [28]. Some studies have
observed an association between the occurrence
of esp and speciﬁc variants of the housekeeping
gene purK (phosphoribosylaminoimidazole carb-
oxylase ATPase subunit), which is a gene that
has been used for typing VREFM [24,25,29,30].
Willems et al. [25] suggested that the purK allele
may be useful as a marker for epidemic VREFM
genogroups in infection control.
Homan et al. [30] have proposed a scheme for
characterisation of E. faecium by multilocus se-
quence typing (MLST). An advantage of MLST for
epidemiological investigations and surveillance is
that it allows easy comparison of local isolates
with all strains contained in an electronic data-
base (http://efaecium.mlst.net/). The eBURST
program permits analysis of the MLST dataset
into non-overlapping groups of related sequence
types (STs) or clonal complexes, and then indi-
cates the predicted progenitor and the evolution-
ary relationship of isolates [31].
Recent studies have shown that VanA E. fae-
cium isolates in Brazil have a number of different
pulsed-ﬁeld gel electrophoresis proﬁles, indica-
ting that several strains are involved in infection
and colonisation of patients [7,8]. However, the
carriage of virulence factors and the MLST pro-
ﬁles of E. faecium isolates from Brazil have not
been investigated previously. The present study
aimed to determine the sequence-based related-
ness of isolates from Brazil by MLST, and then to
relate these ﬁndings to the presence of known
virulence traits.
MATERIALS AND METHODS
Bacteria
Fifty-six isolates of E. faecium were investigated in this study:
ten vancomycin-sensitive E. faecium isolates that colonised
hospitalised patients (VSERM chp) and one infection-derived
vancomycin-sensitive isolate from a hospitalised patient
(VSEFM ihp) were chosen randomly from the collection of
Maschieto et al. [32]; 12 VSEFM isolates that colonised healthy
humans (chh), unrelated to the hospital environment, were
collected from undergraduate students of the University of Sa˜o
Paulo; ten VSEFM isolates from the faeces of pigs (fp) were
collected randomly from two different farms, 300 km apart
(Braganca Paulista and Ribeirao Preto); ten vancomycin-
resistant infection-derived isolates from hospitalised patients
(VREFM ihp), and 13 vancomycin-resistant isolates that colo-
nised hospitalised patients (VREFM chp) were obtained from
the southern part of Brazil [5,7,8,10]. More details concerning
the source of isolates are shown in Table 1.
All isolates were tested for high-level resistance to amino-
glycosides on plates of brain–heart infusion agar (Difco,
Detroit, MI, USA) containing gentamicin (500 mg ⁄L) or strep-
tomycin (2000 mg ⁄L). MICs of vancomycin, quinupristin–
dalfopristin and penicillin were determined using the CLSI
(NCCLS) agar dilution method [33]. PCR was used to
determine the genotype (vanA, vanB, vanD or vanC-1 ⁄ vanC-
2), as described previously [34].
MLST scheme
Internal fragments of seven housekeeping geneswere ampliﬁed
with speciﬁc primers, using reaction conditions described
previously [30]. The genes ampliﬁed were adk, atpA, ddl, gyd,
gdh, purK and pstS. All PCR-ampliﬁed fragments were
sequenced, using both forward and reverse primers and the
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ABI PRISM Big Dye Cycle Sequencing Ready Reaction (PE
Applied Biosystems, Warrington, UK), and were analysed
using an ABI 3100 sequencer (PE Applied Biosystems). In order
to determine single-locus variants (SLVs) within groups of
related isolates (clonal complexes), and to obtain a population
snapshot, the eBURST v.2 program (http://efaecium.mlst.net/)
was used [31].
Genotypic test for virulence traits
Genomic DNA was extracted by detergent lysis [35], and then
200 ng of each DNA sample was bound to a Zeta-Probe nylon
membrane (Bio-Rad, Hercules, CA, USA), using a 96-well
Bio-Dot microﬁltration apparatus (Bio-Rad). DNA was ﬁxed
to the membrane using an ultraviolet multilinker (UVC 515;
Table 1. Phylogenetic characteristics, virulence factors, multilocus sequence typing (MLST) and pulsed-ﬁeld gel
electrophoresis (PFGE) type for isolates of Enterococcus faecium
Strains Alleles
E. faecium Source Date
Susceptibility proﬁle
P ⁄Q-D ⁄HG ⁄HS+
Virulence
factors atpA ddl gdh purK gyd pstS adK ST PFGE
VSfp 4 RP 2003 S ⁄R ⁄ S ⁄ S acm 11 8 10 8 20 9 6 229* ND
VSfp 10 RP 2003 S ⁄R ⁄ S ⁄ S acm 36 8 10 8 20* 9 6 222* ND
VSfp 6 BP 2003 S ⁄R ⁄ S ⁄ S acm 36 8 10 8 20* 9 6 222* ND
VSfp 5 RP 2003 S ⁄R ⁄ S ⁄ S acm 36 8 10 8 20* 9 6 222* ND
VSchp 21 HCFMRP 2001 S ⁄ S ⁄R ⁄R acm 13 21* 8 17 10 27 6 225* ND
VSihp JF9 Lemos-MG 2003 R ⁄R ⁄R ⁄ S acm 13 8 8 8 6 10 6 94 ND
VSchh 04A RP 2004 S ⁄R ⁄ S ⁄ S acm 13 8 8 8 6 10 6 94 ND
VSchh 18A RP 2004 S ⁄R ⁄ S ⁄ S acm 13 8 8 8 6 27 6 178 ND
VSchh 13C RP 2004 S ⁄R ⁄ S ⁄ S acm 13 8 8 8 6 27 11 213* ND
VSchh 05A RP 2004 S ⁄R ⁄ S ⁄ S acm 13 8 8 8 6 27 11 213* ND
VSfp 7 BP 2003 S ⁄ I ⁄ S ⁄ S acm 13 8 8 23 6 10 11 218* ND
VSfp 17 RP 2003 S ⁄ I ⁄ S ⁄ S acm 5 13 26 7 10 6 6 221* ND
VSfp 12 RP 2003 S ⁄R ⁄ S ⁄ S acm 5 13 26* 17 10 26 6 226* ND
VSchp 23 HCFMRP 2001 S ⁄ S ⁄ S ⁄ S acm 5 13 9 15 8 37 6 163 ND
VSchp 22 HCFMRP 2001 S ⁄ S ⁄ S ⁄R acm 5 13 9 15 8 37 6 163 ND
VSchp 20 HCFMRP 2001 S ⁄ S ⁄ S ⁄ S acm 5 13 9 15 8 37 6 163 ND
VSchp 3 HCFMRP 2001 S ⁄ I ⁄ S ⁄ S acm 5 13 9 15 8 37 6 163 ND
VSchp 5 HCFMRP 2001 S ⁄ I ⁄ S ⁄ S acm 5 13 9 15 8 37 6 163 ND
VSfp 11 RP 2003 S ⁄R ⁄ S ⁄ S acm 10 20* 9 17 17 19 6 223* ND
VSchp 9 HCFMRP 2001 S ⁄ S ⁄ S ⁄ S acm 5 13 18 17 17 19 6 211* ND
VSchh 23 RP 2004 S ⁄R ⁄ S ⁄ S acm 36* 13 18 17 10 41* 14* 224* ND
VSchp 18 HCFMRP 2001 S ⁄ S ⁄ S ⁄ S acm 35* 3 25* 2 1 1 1 220* ND
VSchp 14 HCFMRP 2001 S ⁄ S ⁄ S ⁄ S acm 2 3 1 2 1 1 1 22 ND
VSchp 8 HCFMRP 2001 S ⁄ S ⁄ S ⁄ S acm 2 3 1 2 1 1 1 22 ND
VSchh 15B RP 2004 S ⁄ S ⁄ S ⁄ S acm 2 3 1 2 1 1 1 22 ND
VSchh 08A RP 2004 S ⁄R ⁄ S ⁄ S acm 2 3 1 2 1 1 1 22 ND
VSchh 06A RP 2004 S ⁄ S ⁄ S ⁄ S acm 2 3 2 2 1 1 1 214* ND
VSfp 15 RP 2003 S ⁄ I ⁄ S ⁄ S acm 25 3 1 2 10 10 1 219* ND
VRihp 16 CSV-RJ 2001 R ⁄R ⁄R ⁄R acm ⁄ esp ⁄ hyl 1 1 1 1 1 1 1 17 F
VRihp 17 CSV-RJ 2002 R ⁄R ⁄R ⁄R acm ⁄ esp ⁄ hyl 1 1 1 1 1 1 1 17 F
VRchp 15 CSSM-SP 1998 R ⁄R ⁄R ⁄S acm ⁄ hyl ⁄ esp 1 1 1 1 1 1 1 17 C
VRihp 13 CSSM-SP 1998 R ⁄R ⁄R ⁄S acm ⁄ esp ⁄ hyl 1 1 1 1 1 1 1 17 C
VRihp 22 HCSP 1999 R ⁄R ⁄R ⁄R acm 15 1 6 6 1 1 1 50 F
VSchh 16B RP 2004 S ⁄R ⁄ S ⁄ S acm 3 7 3 6 1 1 1 215* ND
VSchh 02A RP 2004 S ⁄ S ⁄ S ⁄ S acm 15 7 5 7 1 1 1 212* ND
VSfp 1 BP 2003 S ⁄R ⁄ S ⁄R acm 21 2 12 9 1 1 5 217* ND
VSchh 25C RP 2004 S ⁄R ⁄ S ⁄ S None 8 4 12 9 1 1 5 130 ND
VSchh 12C RP 2004 S ⁄R ⁄ S ⁄ S acm 15 4 12 6 1 1 5 216* ND
VRchp 24 CSSM-SP 1998 R ⁄R ⁄R ⁄S acm ⁄ esp 5 3 21 18 6 32 3 114 ND
VRchp 14 CSSM-SP 1998 R ⁄R ⁄R ⁄S acm ⁄ esp 5 3 21 18 6 32 3 114 C
VRchp 12 CSSM-SP 1998 R ⁄R ⁄R ⁄ S acm 5 3 21 18 6 32 3 114 C
VRchp 11 CSSM-SP 1998 R ⁄R ⁄R ⁄ S acm 5 3 21 18 6 32 3 114 C
VRchp 10 CSSM-SP 1998 R ⁄R ⁄R ⁄ S acm ⁄ esp 5 3 21 18 6 32 3 114 C
VRchp 9 CSSM-SP 1998 R ⁄R ⁄R ⁄ S acm 5 3 21 18 6 32 3 114 C
VRchp 8 CSSM-SP 1998 R ⁄R ⁄R ⁄ S acm 5 3 21 18 6 32 3 114 C
VRchp 7 CSSM-SP 1998 R ⁄R ⁄R ⁄ S acm 5 3 21 18 6 32 3 114 C
VRchp 6 CSSM-SP 1998 R ⁄R ⁄R ⁄S acm ⁄ esp 5 3 21 18 6 32 3 114 C
VRchp 5 CSSM-SP 1998 R ⁄R ⁄R ⁄R acm 5 3 21 18 6 32 3 114 C
VRchp 4 CSSM-SP 1998 R ⁄R ⁄R ⁄ S acm 5 3 21 18 6 32 3 114 G
VRchp 3 CSSM-SP 1998 R ⁄R ⁄R ⁄ S acm 5 3 21 18 6 32 3 114 G
VRihp 23 HSPSP 1999 R ⁄R ⁄R ⁄S acm ⁄ esp 5 3 21 18 6 32 3 114 C
VRihp 19 CSSM-SP 1999 R ⁄R ⁄R ⁄S acm ⁄ esp 5 3 21 18 6 32 3 114 C
VRihp 18 CSSM-SP 1999 R ⁄R ⁄S ⁄R acm ⁄ esp 5 3 21 18 6 32 3 114 ND
VRihp 2 CSSM-SP 1998 R ⁄R ⁄R ⁄S acm ⁄ esp 5 3 21 18 6 32 3 114 C
VRihp 1 CSSM-SP 1998 R ⁄R ⁄R ⁄S acm ⁄ esp 5 3 21 18 6 32 3 114 C
VRihp 25 HCC-PR 1996 R ⁄R ⁄R ⁄R acm 9 24* 1 18 1 1 3 281* ND
P ⁄Q-D ⁄HG ⁄HS+ represents the tested drugs: P, penicillin; Q-D, quinupristin–dalfopristin; HG, high-level gentamicin resistance; HS, high-level streptomycin resistance.
VS, vancomycin-susceptible; VR, vancomycin-resistant; RP, Ribeirao Preto; BP, Braganca Paulista; HCFMRP, Hospital de Clinicas da Faculdade de Medicina de Ribeirao Preto,
Lemos (Minas Gerais), ; CVS-RJ, Clinica Sao Vicente (Rio de Janeiro); CSSM-SP, Casa de Saude Santa Marcelina (Sao Paulo); HCSP, Hospital Saˆo Paulo; HSPSP, Hospital do
Servidor Pu´blico de Sa˜o Paulo; HCC-PR, Hospital das Clı´nicas de Curitiba, Parana; R, resistant; S, sensitive; I, intermediately-resistant; ND, not determined.
The strains that possess the esp, acm and hyl genes are in bold type.
*A new allele or sequence type (ST).
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Ultra-Lum, Carson, CA, USA). Cytolysin (cylLL, cylLS, cylA),
esp, gelE, acm and hyl genes were detected by hybridisation
with speciﬁc probes prepared by PCR using the primers listed
in Table 2.
Aliquots (50 ng) of each probe were denatured before
labelling with [a-32P]dCTP using the RadPrime DNA Labeling
System (Invitrogen, Carlsbad, CA, USA), and were then
hybridised with the membranes overnight at 65C. The
membranes were then washed twice with 2 · SSPE (1 · SSPE
is 180 mM NaCl, 10 mM NaH2PO4, 1 mM EDTA, pH 7.4) plus
SDS 0.1% w ⁄v for 10 min at room temperature, and then
washed once with 1 · SSPE plus SDS 0.1% w ⁄v for 15 min at
65C. The membranes were exposed to BioMax MR-1 Film for
18–24 h. The following strains were used as positive controls
for each gene: E. faecium TX0016 (hylEfm gene) [12]; E. faecium
TX2555 (acm) [12]; E. faecalis MMH594 (esp and cytolysin
genes) [36]; and E. faecalis OG1RF (gelE) [37].
Phenotypic tests for virulence traits
Cytolysin production was detected by observing b-haemolysis
surrounding colonies on brain–heart infusion agar supple-
mented with human erythrocytes 5% v ⁄v [22]. Gelatinase
production was detected on plates made with Todd–Hewitt
broth (Difco) containing gelatin 30 g ⁄L, and solidiﬁed with
agar. A turbid zone around the colony after incubation for 24 h
at 37C and 4 h at 4C was measured as an index of production
of gelatinase [17].
RESULTS
Susceptibility proﬁles and virulence factors
Susceptibility proﬁles and virulence factors deter-
mined for each isolate are listed in Table 1. All
VRE ST-17, all VREFM ihp ST-114, and four of 12
VREFM chp ST-114 isolates carried the esp gene
(Table 1). Fifty-ﬁve (98%) isolates carried the
acm gene, with the exception being VSEFM chh
25C (ST-130), which carried none of the virulence
genes tested. The hyaluronidase gene (hyl) was
detected in only four isolates (VREFM chp 15,
VREFM ihp 17, VREFM ihp 16 and VREFM ihp
13). All hyl-positive isolates were VRE and
belonged to ST-17. The cytolysin genes and the
gelE gene were not detected in any isolate in this
study, although isolate VREFM ihp 17 showed
apparent gelatinase activity.
MLST
Each housekeeping gene sequenced was as-
signed an allelic number corresponding to
sequences already in the database, or was
assigned a new number by the curator of the
database (http://efaecium.mlst.net/). Based on
the seven allelic numbers assigned, each isolate
was allocated to a speciﬁc ST. The ten VSEFM fp
isolates represented eight new STs, and eight of
12 VSEFM chh isolates were allocated to seven
new STs. The new allelic numbers and new STs
identiﬁed in this study are indicated by asterisks
in Table 1.
In total, 26 different STs were identiﬁed among
the 56 isolates studied. All purK-1 alleles occurred
in ST-17 isolates. Among the 26 STs, eBURST
identiﬁed three groups of related isolates and 19
ungrouped isolates. The ﬁrst group comprised
ﬁve isolates belonging to three STs, ST-178, ST-94
and ST-213. Only one isolate (VSEFM chh 18A)
belonged to ST-178, while ST-94 (VSEFM chh 04
and VSEFM iph JF9) and ST-213 (VSEFM chh 05A
Table 2. Sequences of primers de-
signed to amplify probes for viru-
lence factor genes of Enterococcus
faecium
Gene (GenBank
accession number) Primers
Amplicon
size (bp)
Annealing
temperature
(C)
Cytolysin
cylLL
(L37110)
F 5¢-AACTAAGTGTTGAGGAAATG
R 5¢- AAAGACACAACTACAGTTAC
159 52
cylLS
(L37110)
F 5¢-AGAACTTGTTGGTCCTTC
R 5¢-GCTGAAAATAATGCACCTAC
134 52
cylA
(L37110)
F 5¢-ACAGGTTATGCATCAGATCT
R 5¢-AATTCACTCTTGGAGCAATC
507 52
Enterococcal surface protein
espa
(AY322150)
14F 5¢-AGATTTCATCTTTGATTC TTGG
12R 5¢-AATTGATTCTTTAGCATCTGG
500 50
Hyaluronidase
hylefm
(AF544400)
F 5¢-CGATGCGCAAGAATTAGACA
R 5¢-CATGATTGGACAACCGAGTG
308 52
Adhesin
acm
(AY135217)
F 5¢-GGCCAGAAACGTAACCGATA
F 5¢-CGCTGGGGAAATCTTGTAAA
353 52
Gelatinase
gelE
(M37185)
F 5¢-AATTGCTTTACACGGAACGG
R 5¢-GAGCCATGGTTTCTGGTTGT
548 52
aThe sequences of the E. faecium esp primers were provided by N. Shankar, College of Pharmacy, Oklahoma
University Health Sciences Center, OK, USA.
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and VSEFM chh 13C) are double-locus variants of
each other, and both are SLVs of ST-178 (Fig. 1A).
When the STs found in this study were compared
with all STs registered in the MLST database, it
was observed that ST-94 was related to three
additional SLV STs (ST-60, ST-61 and ST-40).
Therefore, ST-94 is considered to be a founder of
group number 1 (Fig. 1B).
The second group shows that ST-22 and ST-214
are SLVs of each other. Three isolates belonged to
ST-22 (VSEFM chh 08A, VSEFM chp 14 and
VSEFM chp 8), and one isolate was identiﬁed as
ST-214 (VSEFM chh 06A). When compared with
the public MLST database, ST-22 appears to be the
founder of a large group of STs, and ST-214 has
ST-36 as an SLV (Fig. 1B).
The third group consisted of ST-222 and ST-
229, and this group was not connected to any ST
identiﬁed previously in the database. Only one
isolate was typed as ST-229 (VSEFM fp 4), and
three isolates belonged to ST-222 (VSEFM fp 5,
VSEFM fp 6 and VSEFM fp 10) (Fig. 1).
All remaining isolates were ungrouped, with
no SLVs identiﬁed from this study. However,
when compared with the database, eBURST
identiﬁed a number of SLV groups, and identiﬁed
possible progenitors. Thus, ST-217 (VSEFM fp 1)
formed a group with ST-44; ST-212 formed a
group with ST-27 and ST-28; and ST-17 was part
of a group with several related STs (ST-78, ST-209,
ST-42 and ST-16) (Fig. 1). Among the 23 vanco-
mycin-resistant enterococcal isolates from Brazil,
four were ST-17, 17 were ST-114 (including
VREFM ihp and VREFM chp), one was ST-281
(VREFM ihp 25, a VanD variant), and one was ST-
50.
DISCUSSION
Genes for the enterococcal virulence factors
cytolysin and gelatinase were not detected among
the 56 E. faecium isolates studied, consistent with
the ﬁndings of other studies [38, 39]. Interestingly,
one isolate was positive for gelatinase activity, but
Fig. 1. A, eBURST diagram of the
population analysis of Enterococcus
faecium isolates from Brazil. B,
eBURST diagram of the analysis of
the sequence types (STs) of the
Brazilian isolates and the entire
public E. faecium MLST database
(all STs assigned). The size of the
dots depends on the number of
strains. Grey dots indicate the pro-
genitor of each group. The numbers
correspond to the STs. The dashed-
circled STs are those found in this
study, with the STs forming clonal
complexes being linked by lines. The
arrow indicates ST-17, one of the STs
determined among the vancomycin-
resistant enterococci from Brazil.
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no gene was detected. This may indicate the rare
occurrence of a divergent gelatinase gene in some
strains of E. faecium, or alternatively, the presence
of an additional protease that yields cleavage
products which behave similarly to those gener-
ated by E. faecalis gelatinase in this test.
The esp gene was restricted to vancomycin-
resistant isolates, with 13 (56%) of the VREFM
isolates analysed being positive for esp. Five of 13
esp-positive strains were from VREFM colonising
hospitalised patients (chp), and eight of 13 were
infection isolates, representing 80% of the VREFM
ihp group. The hyl gene was rare among VREFM
isolates from Brazil, being found in only 17% of
VREFM isolates in this study. All hyl-positive
isolates were also esp-positive. Rice et al. [12]
detected hyl in 38% of non-stool VREFM isolates
and in 33% of stool VREFM isolates from the USA.
Vankerckoven et al. [16] detected esp in 65% and
hyl in 17% of 271 isolates from Europe, with
hyl being detected in 27% of VREFM clinical
isolates, compared with only 14% of the faecal
isolates. Similarly, esp was detected in 92% of
clinical and 73% of faecal VREFM isolates, and
the prevalence of espwas higher in VREFM than in
VSEFM (77% vs. 53%, respectively) [16]. In
Brazil, none of the VSEFM isolates were
esp-positive.
The present study included isolates from 1998
(after the ﬁrst outbreak of VRE in Brazil) and from
1999 (collected during a survey in the same
hospital). All isolates from 1999 were esp-positive,
as were some of the isolates from 1998. It is
known that esp can be deleted from the patho-
genicity island of E. faecalis at a high frequency
[27], but the mechanism of its acquisition is
unknown. Oancea et al. [40] demonstrated that
the esp gene is transferable by conjugation among
enterococcal isolates. Because of the temporal
relationship between related isolates that were
esp-positive in the present study, it seems that esp
may have been acquired by E. faecium during the
ﬁrst outbreak.
MLST analysis showed that VSEFM isolates
from the faeces of pigs in Brazil are distinct from
all human isolates studied previously. All VREFM
isolates studied could be assigned to four differ-
ent STs (ST-114, ST-17, ST-281 and ST-50). Most
isolates from the ﬁrst outbreak in Brazil were
classiﬁed as ST-114, and only two were ST-17.
However, the VREFM iph 23 isolate, from a
different hospital in the city of Sa˜o Paulo, was
also ST-114, which indicates possible inter-hospi-
tal dissemination.
Two isolates from 1999 (Sa˜o Paulo city), and
two from Rio de Janeiro (one in 2000 and the other
in 2001), were allocated to ST-17. The housekeep-
ing gene purK allele 1 (purK-1) is present in ST-17,
and is linked to the presence of esp. All ST-17
isolates possessed the hyl gene, which was not
detected in any of the other isolates. The E. faecium
MLST database contains several VRE registered as
ST-17 from different geographical areas, namely
the UK, the USA, France and The Netherlands.
Willems et al. [25] reported several isolates that
harboured purK-1, and noted that all were also
esp-positive. More recently, Bonora et al. [29]
identiﬁed purK-1 in all epidemic VREFM isolates
studied between 2000 and 2001 in northern Italy.
All were esp-positive and clustered in ST-78, an
SLV of ST-17. Werner et al. [41] described a proﬁle
related to ST-17 in a clinical isolate from Germany,
and Willems et al. [42] considered that ST-17 was
an example of cumulative evolutionary processes
that improved the relative ﬁtness of bacteria
in hospital environments. These observations
indicate that VREFM ST-17 and its SLVs are
distributed unusually widely. The presence of
four ST-17 isolates in the present study reinforces
the importance of surveillance programmes to
avoid the spread of this lineage in hospitals.
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